

POSTER PRESENTATION

Open Access

Development of novel vaccine candidates and challenge models for *Plasmodium vivax*

Eduardo Alves^{1*}, Ahmed Salman^{1,2}, Chris Janse², Shahid Khan², Adrian Hill¹, Arturo Reyes-Sandoval¹

From Challenges in malaria research: Core science and innovation
Oxford, UK. 22-24 September 2014

Plasmodium vivax is the most widely distributed human malaria parasite in the world and despite nearly 2.5 billion people living at risk, only four vaccines have been assessed in phase I clinical trials and only one has progressed to a phase II trial showing no sterile efficacy. We started to develop new challenge models to assess the efficacy of several new *P. vivax* pre-erythrocytic vaccine candidates (PVX_091700; PVX_121950; PVX_084090; PVX_099035; PVX_095375; PVX_000975; PVX_003665; PVX_000810) in mice. Our model is based on creating mutant *P. berghei* (rodent malaria) lines expressing *P. vivax* antigens through a new method called "Gene Insertion/Marker out" (GIMO). In addition, we are cloning the *P. vivax* pre-erythrocytic vaccine candidates in recombinant chimpanzee adenovirus (ChAd) and modified vaccine Ankara (MVA) vectors. Upon generation of transgenic parasites and recombinant viruses, a faster assessment to determinate the efficacy of all new *P. vivax* vaccine candidates can be achieved by using prime/boost immunization regimens followed by a challenge with corresponding transgenic chimera parasites.

Authors' details

¹Oxford University, Oxford, UK. ²Leiden Malaria Research Group, Leiden, The Netherlands.

Published: 22 September 2014

doi:10.1186/1475-2875-13-S1-P4

Cite this article as: Alves et al.: Development of novel vaccine candidates and challenge models for *Plasmodium vivax*. *Malaria Journal* 2014 **13**(Suppl 1):P4.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Oxford University, Oxford, UK

Full list of author information is available at the end of the article